Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 1/20 | 0.55 |
| ▸ | CCKAR | P32238 | 2/20 | 0.44 |
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5556676 | 0.83 | DPP4 (0.47) | CASR | |
| SCHEMBL5552595 | 0.77 | CTSS (0.63) | CTSLCTSSCTSK | |
| SCHEMBL5556766 | 0.75 | CTSS (0.69) | CTSLCTSSCTSKCCKBR | |
| SCHEMBL5556732 | 0.75 | CTSS (0.69) | CTSLCTSSCTSKCCKBR | |
| SCHEMBL5556628 | 0.74 | CTSS (0.76) | CTSLCTSSCTSK | |
| SCHEMBL999047 | 0.74 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL29908025 | 0.74 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL29828648 | 0.74 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL999046 | 0.74 | CTSS (0.76) | CTSLCTSSCTSKACE | |
| SCHEMBL3599165 | 0.74 | CTSS (0.76) | CTSLCTSSCTSKACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | CTSL 226/4885CTSS 596/4885CTSK 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.